Sclerostin and CKD-MBD

Susan C Schiavi1

  • 1Genzyme, Boston, MA, USA, scschiavi@gmail.com.

Insights

Declining kidney function alters mineral balance, affecting bones and the cardiovascular system. Elevated sclerostin, a protein linked to kidney disease, impacts bone health and may influence cardiovascular calcification.

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Biology

Background:

  • Chronic kidney disease (CKD) disrupts mineral homeostasis, leading to skeletal and cardiovascular complications.
  • Osteocyte-derived sclerostin increases with renal injury, inhibiting bone formation via Wnt/β-catenin signaling.
  • The role of Wnt/β-catenin signaling in CKD-mineral and bone disorder (CKD-MBD) is complex, with potential dual effects on bone and vasculature.

Purpose of the Study:

  • To explore the role of sclerostin and Wnt/β-catenin signaling in the systemic changes associated with declining kidney function.
  • To understand the differential skeletal effects of agents targeting β-catenin signaling in the context of CKD.
  • To investigate the relationship between circulating sclerostin levels and cardiovascular disease progression in CKD patients.

Main Methods:

  • Review of current literature on sclerostin, Wnt/β-catenin signaling, and CKD-MBD.
  • Analysis of existing epidemiological data on sclerostin and cardiovascular outcomes in CKD.
  • Discussion of the molecular mechanisms linking renal function, bone metabolism, and vascular health.

Main Results:

  • Elevated sclerostin is an early indicator of renal injury, correlating with reduced bone formation.
  • Wnt/β-catenin signaling inhibition by sclerostin contributes to diverse forms of renal osteodystrophy.
  • Emerging data suggests Wnt/β-catenin signaling may have protective roles in cardiovascular health despite its role in calcification.

Conclusions:

  • Sclerostin and Wnt/β-catenin signaling are critical mediators in CKD-MBD, influencing both skeletal and cardiovascular health.
  • Further epidemiological studies are needed to elucidate the precise role of sclerostin in CKD progression and cardiovascular disease.
  • Understanding these pathways is crucial for developing targeted therapies for CKD complications.

Related Concept Videos

Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
3.1K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K